Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520208 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase 2 study of Acute Promyelocytic Leukemia, sponsored by CytRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT00520208 is a Phase 2 study of Acute Promyelocytic Leukemia that has completed, run by CytRx. The registered enrollment target is 15 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00520208, a Phase 2 study of Acute Promyelocytic Leukemia, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Patients must have received and failed therapy with ATRA and ATO. Treatment may have been administered either as combination therapy or sequentially as single agents. Patients who are intolerant to either drug are eligible for this study.
Conditions Studied
Interventions
- DRUG Tamibarotene
Study Locations (2)
Illinois
- Northwestern University - Chicago
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520208
The ClinicalTrials.gov registry entry for NCT00520208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Promyelocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Tamibarotene is the first listed.
NCT00520208 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT00520208 about?
NCT00520208 is a clinical study titled "Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL". This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Patients mu...
What is the current status of trial NCT00520208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-09. Estimated completion is 2013-01.
What conditions does trial NCT00520208 study?
This clinical trial studies the following conditions: Acute Promyelocytic Leukemia.
What interventions are being tested in trial NCT00520208?
The interventions under investigation include: Tamibarotene (DRUG).
Who is sponsoring clinical trial NCT00520208?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520208 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Promyelocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.